Rigel Pharmaceuticals, Inc. (RIGL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RIGL Revenue Growth
Revenue Breakdown (FY 2025)
RIGL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RIGL Revenue Analysis (2014–2025)
As of May 6, 2026, Rigel Pharmaceuticals, Inc. (RIGL) generated trailing twelve-month (TTM) revenue of $299.8 million, reflecting strong growth of +10.3% year-over-year. The most recent quarter (Q1 2026) recorded $58.8 million in revenue, down 15.7% sequentially.
Looking at the longer-term picture, RIGL's 5-year compound annual growth rate (CAGR) stands at +22.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $294.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RIGL's business is primarily driven by Product (107%), Contract revenues from collaborations (29%), and Government Contract (0%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PRTA (-92.8% YoY), FOLD (+21.3% YoY), and RARE (+13.3% YoY), RIGL has underperformed the peer group in terms of revenue growth. Compare RIGL vs PRTA →
RIGL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RIGLCurrent | $300M | +10.3% | +22.1% | 42.6% | |
 PRTA | $10M | -92.8% | +62.6% | -1905.8% | |
 FOLD | $528M | +21.3% | +23.7% | 4.7% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 PTCT | $1.7B | +114.5% | +35.4% | 49.5% |
RIGL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $294.3M | +64.1% | $274.7M | 93.3% | $125.5M | 42.6% |
| 2024 | $179.3M | +53.4% | $160.6M | 89.6% | $24.2M | 13.5% |
| 2023 | $116.9M | -2.8% | $109.8M | 93.9% | $-20,491,000 | -17.5% |
| 2022 | $120.2M | -19.4% | $118.5M | 98.5% | $-55,550,000 | -46.2% |
| 2021 | $149.2M | +37.4% | $148.2M | 99.3% | $-12,496,000 | -8.4% |
| 2020 | $108.6M | +83.2% | $107.7M | 99.2% | $-28,973,000 | -26.7% |
| 2019 | $59.3M | +33.2% | $58.4M | 98.5% | $-69,091,000 | -116.5% |
| 2018 | $44.5M | +892.6% | $44.2M | 99.4% | $-72,683,000 | -163.3% |
| 2017 | $4.5M | -78.0% | $-41,785,000 | -931.9% | $-79,616,000 | -1775.6% |
| 2016 | $20.4M | -29.5% | $-43,063,000 | -211.3% | $-69,741,000 | -342.2% |
See RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RIGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
Is RIGL's revenue growth accelerating or slowing?
RIGL maintains +10.3% revenue growth, in line with its 5-year CAGR of +22.1%. TTM revenue stands at $300M. Growth rate remains consistent with historical average.
What is RIGL's long-term revenue growth rate?
Rigel Pharmaceuticals, Inc.'s 5-year revenue CAGR of +22.1% reflects the sustained expansion pattern. Current YoY growth of +10.3% is near this long-term average.
How is RIGL's revenue distributed by segment?
RIGL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.